Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | RXRB | P28702 | 2/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815536 | 0.94 | — | — | |
| SCHEMBL17811469 | 0.82 | RAB9A (0.48) | RAB9AHPGDNPC1MEN1KMT2A | |
| SCHEMBL17811468 | 0.78 | MEN1 (0.53) | RAB9AHPGDNPC1MEN1KMT2A | |
| SCHEMBL17811491 | 0.75 | ACHE (0.42) | HPGDRXRARXRBRXRGPDE4A | |
| SCHEMBL20306696 | 0.75 | ALDH1A1 (0.46) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL17811470 | 0.72 | ALDH1A1 (0.41) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6937372 | 0.69 | ALDH1A1 (0.56) | RAB9AHPGDNPC1MEN1KMT2A | |
| SCHEMBL17811476 | 0.69 | ESRRG (0.34) | KMT2A | |
| SCHEMBL17815439 | 0.69 | NR1H2 (0.37) | RXRARXRBRXRGPDE4APDE4B | |
| SCHEMBL4585188 | 0.69 | RAB9A (0.44) | RAB9AHPGDNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | TRINSEO EUROPE GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | ELOVL5, ELOVL3, ELOVL1 | RAB9A 4875/4885HPGD 1418/4885NPC1 4515/4885 |
| US-20160159956-A1 | Polymerisation Initiators | ELOVL5, ELOVL3, ELOVL1 | RAB9A 4875/4885HPGD 1418/4885NPC1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.